Navigation Links
Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
Date:5/8/2013

arch 31, 2013 and December 31, 2012; noshares issued and outstanding atMarch 31, 2013 and December 31, 2012--Common stock, $.001 par value, 300,000,000shares authorized at March 31, 2013 andDecember 31, 2012 and;92,641,567 and 84,413,670 shares issued and outstanding at March 31, 2013 and December 31, 2012, respectively

9384Additional paid-in capital 

514,678512,174Accumulated other comprehensive income (loss)

1315Accumulated deficit

(456,172)(436,804)Total stockholders' equity 

58,61275,469Total liabilities and stockholders' equity 

$
,738$
39,154 

 

 

Orexigen Therapeutics, Inc.Statements of Operations(In thousands, except per share amounts)(Unaudited)Three Months Ended March 31, 20132012Revenues:Collaborative agreement $

857$

857License revenue 00Total revenues 857857Operating expenses:Research and development 15,1556,800General and administrative 5,1004,512Total operating expenses 20,25511,312Loss from operations (19,398)(10,455)Other income (expense):Interest income 3143Interest expense and other(1)(2)Total other income (expense) 3041Net loss $

(19,368)$

(10,414)Net loss per share - basic and diluted $

(0.21)$

(0.16)Shares used in computing net loss per share – basic and diluted 90,33665,989 

 


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Orexigen Therapeutics to Present at Upcoming Conferences
2. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
3. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
5. Nile Therapeutics Reports 2011 Third Quarter Financial Results
6. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
7. Fate Therapeutics Strengthens Its iPSC Platform
8. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
9. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
10. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
11. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... The young Swiss biotech,enterprise AMVAC AG has gained ... most renowned vaccine specialists. Prof. Klein, who was,formerly ... Aventis-Pasteur,Group, will immediately assume directorship of the scientific ... vaccinologist has,access to an outstanding network across one ...
... to Realize ... Critical Path Initiative Goals, MOUNTAIN VIEW, Calif., ... provider of software,strategic consulting, and regulatory services for optimizing clinical ... chief technology officer, has been invited to speak to U.S.,and ...
... PXS; Nasdaq: PXSL) today announced that it had ... Asian and European institutions,and professional investors. The placement ... a series of international Phase III,trials and embarks ... Pharmaxis will issue 12.8 million new fully ...
Cached Biology Technology:Prof. Michel Klein Becomes Chief Scientific Officer at AMVAC 2Pharsight Invited to Present on Winning Strategies for R&D Productivity at New York Pharma Forum on October 15, 2007 2Pharsight Invited to Present on Winning Strategies for R&D Productivity at New York Pharma Forum on October 15, 2007 3Pharmaxis Announces Placement of $50 Million and Share Purchase Plan 2
(Date:12/17/2014)... 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend upcoming ... medical sensors in biomedical applications. Chemical sensors help ... correct diagnosis during surgical procedures. The Global Chemical ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ...  report to their offering. One ... in technology. With continuous advances in technology, it ... latest standard that meets the needs and expectations ...
(Date:12/11/2014)... PAUL, Minn. , Dec. 10, 2014 /PRNewswire/ ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ... Adding functional endpoints to toxicology studies ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... (SALT LAKE CITY)Alternating hemiplegia of childhood (AHC) is a ... episodes of paralysis and stiffness, first affecting one side ... and disappear, again and again, and affected children often ... older, children fall progressively behind their peers in both ...
... smog-filled sky or a contaminated river, according to a ... for the prosperous. People living in China,s cities ... more likely to begreen: re-using their plastic grocery bags ... the international journal AMBIO , indicates that the ...
... doesn,t mean making a trip to the local pharmacy for ... the forest to provide a pharmacopeia of medicines to ... But while questions persist about whether such natural remedies are ... examining the phenomenon from a unique perspective, and trying to ...
Cached Biology News:Gene mutations linked to most cases of rare disorder -- Alternating Hemoplegia of Childhood 2Gene mutations linked to most cases of rare disorder -- Alternating Hemoplegia of Childhood 3Pollution can make citizens - both rich and poor - go green 2Health care savings, naturally 2Health care savings, naturally 3
... 5 ml of DETACHaBEAD 19 polyclonal ... CD19 (Pan B). B cells ... and released with DETACHaBEAD CD19 are ... suitable for applications such as culturing ...
This Malachite Green Phosphate Detection Kit...
5-bromo-4-chloro-3-indolyl b -D-galactopyranoside (X-Gal)...
...
Biology Products: